145 related articles for article (PubMed ID: 34369425)
21. CDKN2A point mutations D153spl(c.457G>T) and IVS2+1G>T result in aberrant splice products affecting both p16INK4a and p14ARF.
Rutter JL; Goldstein AM; Dávila MR; Tucker MA; Struewing JP
Oncogene; 2003 Jul; 22(28):4444-8. PubMed ID: 12853981
[TBL] [Abstract][Full Text] [Related]
22. The 9p21.3 risk of childhood acute lymphoblastic leukaemia is explained by a rare high-impact variant in CDKN2A.
Vijayakrishnan J; Henrion M; Moorman AV; Fiege B; Kumar R; da Silva Filho MI; Holroyd A; Koehler R; Thomsen H; Irving JA; Allan JM; Lightfoot T; Roman E; Kinsey SE; Sheridan E; Thompson PD; Hoffmann P; Nöthen MM; Mühleisen TW; Eisele L; Bartram CR; Schrappe M; Greaves M; Hemminki K; Harrison CJ; Stanulla M; Houlston RS
Sci Rep; 2015 Oct; 5():15065. PubMed ID: 26463672
[TBL] [Abstract][Full Text] [Related]
23. Melanoma candidate genes CDKN2A/p16/INK4A, p14ARF, and CDK4 sequencing in patients with uveal melanoma with relative high-risk for hereditary cancer predisposition.
Abdel-Rahman MH; Pilarski R; Massengill JB; Christopher BN; Noss R; Davidorf FH
Melanoma Res; 2011 Jun; 21(3):175-9. PubMed ID: 21412176
[TBL] [Abstract][Full Text] [Related]
24. Contributions of IKZF1, DDC, CDKN2A, CEBPE, and LMO1 Gene Polymorphisms to Acute Lymphoblastic Leukemia in a Yemeni Population.
Al-Absi B; Razif MFM; Noor SM; Saif-Ali R; Aqlan M; Salem SD; Ahmed RH; Muniandy S
Genet Test Mol Biomarkers; 2017 Oct; 21(10):592-599. PubMed ID: 28768142
[TBL] [Abstract][Full Text] [Related]
25. The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanoma.
Lesueur F; de Lichy M; Barrois M; Durand G; Bombled J; Avril MF; Chompret A; Boitier F; Lenoir GM; ; Bressac-de Paillerets B; Baccard M; Bachollet B; Berthet P; Bonadona V; Bonnetblanc JM; Caron O; Chevrant-Breton J; Cuny JF; Dalle S; Delaunay M; Demange L; De Quatrebarbes J; Doré JF; Frénay M; Fricker JP; Gauthier-Villars M; Gesta P; Giraud S; Gorry P; Grange F; Green A; Huiart L; Janin N; Joly P; Kérob D; Lasset C; Leroux D; Limacher JM; Longy M; Mansard S; Marrou K; Martin-Denavit T; Mateus C; Maubec E; Olivier-Faivre L; Orlandini V; Pujol P; Sassolas B; Stoppa-Lyonnet D; Thomas L; Vabres P; Venat L; Wierzbicka E; Zattara H
Br J Cancer; 2008 Jul; 99(2):364-70. PubMed ID: 18612309
[TBL] [Abstract][Full Text] [Related]
26. Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctr1.
Zhang S; Ramsay ES; Mock BA
Proc Natl Acad Sci U S A; 1998 Mar; 95(5):2429-34. PubMed ID: 9482902
[TBL] [Abstract][Full Text] [Related]
27. CDKN2A exon 1B deletion predisposing to melanoma and neural system tumour syndrome.
Wong SL; Martiniuc D; Kiuru M
Clin Exp Dermatol; 2022 Dec; 47(12):2284-2285. PubMed ID: 35904890
[TBL] [Abstract][Full Text] [Related]
28. Chimeras of p14ARF and p16: functional hybrids with the ability to arrest growth.
Williams RT; Barnhill LM; Kuo HH; Lin WD; Batova A; Yu AL; Diccianni MB
PLoS One; 2014; 9(2):e88219. PubMed ID: 24505435
[TBL] [Abstract][Full Text] [Related]
29. The prognostic significance of CDKN2A, CDKN2B and MTAP inactivation in B-lineage acute lymphoblastic leukemia of childhood. Results of the EORTC studies 58881 and 58951.
Mirebeau D; Acquaviva C; Suciu S; Bertin R; Dastugue N; Robert A; Boutard P; Méchinaud F; Plouvier E; Otten J; Vilmer E; Cavé H;
Haematologica; 2006 Jul; 91(7):881-5. PubMed ID: 16818274
[TBL] [Abstract][Full Text] [Related]
30. A mutation hotspot at the p14ARF splice site.
Harland M; Taylor CF; Chambers PA; Kukalizch K; Randerson-Moor JA; Gruis NA; de Snoo FA; ter Huurne JA; Goldstein AM; Tucker MA; Bishop DT; Bishop JA
Oncogene; 2005 Jun; 24(28):4604-8. PubMed ID: 15856016
[TBL] [Abstract][Full Text] [Related]
31. Germline mutation of ARF in a melanoma kindred.
Hewitt C; Lee Wu C; Evans G; Howell A; Elles RG; Jordan R; Sloan P; Read AP; Thakker N
Hum Mol Genet; 2002 May; 11(11):1273-9. PubMed ID: 12019208
[TBL] [Abstract][Full Text] [Related]
32. CDKN2a/p16INK4a mutations and lack of p19ARF involvement in familial melanoma kindreds.
Fargnoli MC; Chimenti S; Keller G; Soyer HP; Dal Pozzo V; Höfler H; Peris K
J Invest Dermatol; 1998 Dec; 111(6):1202-6. PubMed ID: 9856841
[TBL] [Abstract][Full Text] [Related]
33. Absence of germline CDKN2A mutation in Sicilian patients with familial malignant melanoma: Could it be a population-specific genetic signature?
Di Lorenzo S; Fanale D; Corradino B; Caló V; Rinaldi G; Bazan V; Giordano A; Cordova A; Russo A
Cancer Biol Ther; 2016; 17(1):83-90. PubMed ID: 26650572
[TBL] [Abstract][Full Text] [Related]
34. A Heritable Missense Polymorphism in CDKN2A Confers Strong Risk of Childhood Acute Lymphoblastic Leukemia and Is Preferentially Selected during Clonal Evolution.
Walsh KM; de Smith AJ; Hansen HM; Smirnov IV; Gonseth S; Endicott AA; Xiao J; Rice T; Fu CH; McCoy LS; Lachance DH; Eckel-Passow JE; Wiencke JK; Jenkins RB; Wrensch MR; Ma X; Metayer C; Wiemels JL
Cancer Res; 2015 Nov; 75(22):4884-94. PubMed ID: 26527286
[TBL] [Abstract][Full Text] [Related]
35. CDKN2A/P16INK4A variants association with breast cancer and their in-silico analysis.
Aftab A; Shahzad S; Hussain HMJ; Khan R; Irum S; Tabassum S
Breast Cancer; 2019 Jan; 26(1):11-28. PubMed ID: 30039340
[TBL] [Abstract][Full Text] [Related]
36. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas.
Elisei R; Shiohara M; Koeffler HP; Fagin JA
Cancer; 1998 Nov; 83(10):2185-93. PubMed ID: 9827724
[TBL] [Abstract][Full Text] [Related]
37. Association of the independent polymorphisms in CDKN2A with susceptibility of acute lymphoblastic leukemia.
Zhou X; Liao F; Zhang J; Qin Y; Xu H; Ding Z; Zhang Y; Zhang F
Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29654170
[TBL] [Abstract][Full Text] [Related]
38. Association of CDKN2A/B mutations, PD-1, and PD-L1 with the risk of acute lymphoblastic leukemia in children.
Ruan Y; Xie L; Zou A
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10841-10850. PubMed ID: 37314514
[TBL] [Abstract][Full Text] [Related]
39. CDKN2A and MC1R analysis in amelanotic and pigmented melanoma.
Ghiorzo P; Pastorino L; Pizzichetta MA; Bono R; Queirolo P; Talamini R; Annessi G; Bruno W; Nasti S; Gargiulo S; Battistuzzi L; Sini MC; Palmieri G; Scarrà GB;
Melanoma Res; 2009 Jun; 19(3):142-5. PubMed ID: 19339902
[TBL] [Abstract][Full Text] [Related]
40. Frequent deletion of p16INK4a/MTS1 and p15INK4b/MTS2 in pediatric acute lymphoblastic leukemia.
Okuda T; Shurtleff SA; Valentine MB; Raimondi SC; Head DR; Behm F; Curcio-Brint AM; Liu Q; Pui CH; Sherr CJ
Blood; 1995 May; 85(9):2321-30. PubMed ID: 7727766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
